NCT01475292View on ClinicalTrials.gov

A Study to Investigate How Safe and Well Tolerated RV568 is in Patients With Chronic Obstructive Pulmonary Disease (COPD)

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

RV568

RV568 50 ug administered via a nebuliser once daily for 14 days

DRUG

RV568

RV568 100 ug administered via a nebuliser once daily for 14 days

DRUG

Placebo

Placebo administered via a nebuliser once daily for 14 days

Trial Locations (2)

Unknown

Quintiles Drug Research Unit at Guy's Hospital, London

Medicines Evaluation Unit (MEU), Manchester

All Listed Sponsors
lead

Respivert Ltd

INDUSTRY

NCT01475292 - A Study to Investigate How Safe and Well Tolerated RV568 is in Patients With Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter | Biotech Hunter